Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
Thrombosis and Haemostasis · 01.02.2023 · 123 (02) · 245-254
DOI: 10.1055/a-1957-6305 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.02.2023. Verfasst von Sanne Bakker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Hemorrhage. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition.
Aims
To determine whether SSRIs are associated with major bleeding during VKA treatment and investigate the possible mechanisms.
Methods
In this cohort study, information on SSRI use and bleeding complications was obtained from patient records of VKA initiators between 2006 and 2018 from two anticoagulation clinics. Conditional logistic regression and time-dependent Cox regression were used to estimate the effect of SSRIs on a high international normalized ratio (INR ≥ 5) within 2 months after SSRI initiation and on major bleeding during the entire period of SSRI use, respectively. SSRI use was stratified for (non-)CYP2C9 inhibitors.
Results
A total of 58,918 patients were included, of whom 1,504 were SSRI users. SSRI initiation versus nonuse was associated with a 2.41-fold (95% confidence interval [CI]: 2.01–2.89) increased risk for a high INR, which was 3.14-fold (95% CI: 1.33–7.43) among CYP2C9-inhibiting SSRI users. The adjusted hazard ratio of major bleeding was 1.22 (95% CI: 0.99–1.50) in all SSRI users and 1.31 (95% CI: 0.62–2.72) in CYP2C9-inhibiting SSRI users compared with nonusers.
Conclusion
SSRI use is associated with an increased risk of high INR and might be associated with major bleeding. The risk of a high INR was slightly more elevated for CYP2C9-inhibiting SSRI users, suggesting there might be a pharmacokinetic interaction (by CYP2C9 inhibition) next to a pharmacodynamic effect of SSRIs on platelet activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Star-shl Thrombosis Service, Rotterdam, The Netherlands.
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Johanna Louise I Burggraaf
Zitieren
APA
Bakker, S., Burggraaf, J. L. I., Kruip, M. J. H. A., van der Meer, F. J. M., Lijfering, W. M., & van Rein, N. (2023). Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study. Thrombosis and Haemostasis, 123(02), 245-254. https://doi.org/10.1055/a-1957-6305
Vancouver
Bakker S, Burggraaf JLI, Kruip MJHA, van der Meer FJM, Lijfering WM, van Rein N. Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study. Thrombosis and Haemostasis. 2023;123(02):245-254. doi:10.1055/a-1957-6305
BibTeX
@article{Bakker2023,
author = {Bakker, Sanne and Burggraaf, Johanna Louise I and Kruip, Marieke J H A and van der Meer, Felix J M and Lijfering, Willem M and van Rein, Nienke},
title = {Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {02},
pages = {245--254},
doi = {10.1055/a-1957-6305}
}
EUVIMED